xanomeline has been researched along with Schizophrenia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Brannan, SK; Breier, A; Kavanagh, S; Miller, AC; Paul, SM; Weiden, PJ | 1 |
| Allen, LA; Baker, E; Brannan, SK; Miller, AC; Paul, SM; Sauder, C | 1 |
| Brannan, SK; Breier, A; Lieberman, JA; Miller, AC; Paul, SM; Sawchak, S | 1 |
| Bryant, ZK; Conn, PJ; Foster, DJ | 1 |
| Lindsley, CW; Melancon, BJ; Panarese, JD; Tarr, JC; Wood, MR | 1 |
| Bymaster, FP; Dubé, S; Felder, CC; Lienemann, J; Lightfoot, J; Mallinckrodt, C; McKinzie, DL; Potter, WZ; Shekhar, A | 1 |
| Davis, JM; Janowsky, DS | 1 |
| Pomara, N | 1 |
| Bridges, TM; Conn, PJ; Hopkins, CR; Jones, CK; LeBois, EP; Lindsley, CW; Wood, MR | 1 |
| Barak, S; Weiner, I | 1 |
| Mirza, NR; Peters, D; Sparks, RG | 1 |
| Bymaster, FP; Fink-Jensen, A; Hart, JC; Jeppesen, L; Peters, SC; Rasmussen, K; Sauerberg, P; Shannon, HE; Sheardown, MJ; Swedberg, MD | 1 |
4 review(s) available for xanomeline and Schizophrenia
| Article | Year |
|---|---|
Targeting muscarinic receptors to treat schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Humans; Muscarinic Agonists; Pyridines; Receptors, Muscarinic; Schizophrenia; Thiadiazoles | 2021 |
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Topics: Allosteric Regulation; Alzheimer Disease; Animals; Brain; Cognition; Drug Design; Humans; Molecular Targeted Therapy; Muscarinic Agonists; Pyridines; Receptor, Muscarinic M1; Schizophrenia; Thiadiazoles | 2013 |
The antipsychotic potential of muscarinic allosteric modulation.
Topics: Allosteric Regulation; Amino Acid Sequence; Animals; Antipsychotic Agents; Humans; Molecular Sequence Data; Pyridines; Receptors, Muscarinic; Schizophrenia; Thiadiazoles | 2010 |
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Topics: Acetylcholine; Animals; Brain; Dopamine; Drug Evaluation; Gene Expression; Humans; In Vitro Techniques; Muscarinic Agonists; Pyridines; Receptors, Muscarinic; Schizophrenia; Thiadiazoles | 2003 |
4 trial(s) available for xanomeline and Schizophrenia
| Article | Year |
|---|---|
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Pyridines; Schizophrenia; Thiadiazoles; Treatment Outcome | 2022 |
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
Topics: Cognitive Dysfunction; Humans; Pyridines; Quaternary Ammonium Compounds; Schizophrenia; Thiadiazoles | 2022 |
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzilates; Cholinergic Antagonists; Double-Blind Method; Drug Combinations; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Muscarinic Agonists; Nortropanes; Pyridines; Schizophrenia; Thiadiazoles | 2021 |
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Topics: Adolescent; Adult; Affect; Brief Psychiatric Rating Scale; Cognition Disorders; Demography; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Neuropsychological Tests; Pyridines; Receptors, Cholinergic; Receptors, Muscarinic; Schizophrenia; Severity of Illness Index; Thiadiazoles | 2008 |
5 other study(ies) available for xanomeline and Schizophrenia
| Article | Year |
|---|---|
Antipsychotic properties of muscarinic drugs.
Topics: Animals; Antipsychotic Agents; Cholinergic Agents; Cholinesterase Inhibitors; Humans; Isoflurophate; Physostigmine; Psychoses, Substance-Induced; Pyridines; Rats; Schizophrenia; Thiadiazoles | 2009 |
Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
Topics: Acetylcholine; Cognition Disorders; Dopamine; Hippocampus; Humans; Muscarinic Agonists; Neocortex; Pyridines; Receptor, Muscarinic M1; Schizophrenia; Thiadiazoles | 2009 |
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Topics: Amphetamine; Animals; Antimanic Agents; Behavior, Animal; Cognition Disorders; Dizocilpine Maleate; Dose-Response Relationship, Drug; Kinetics; Male; Molecular Targeted Therapy; Muscarinic Agonists; Neural Inhibition; Neurotransmitter Agents; Pyridines; Rats; Rats, Wistar; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Scopolamine; Tachyphylaxis; Thiadiazoles | 2011 |
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Costs; Drugs, Investigational; Humans; Olanzapine; Pirenzepine; Placebos; Pyridines; Randomized Controlled Trials as Topic; Schizophrenia; Thiadiazoles | 1996 |
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Brain; Cholinergic Agonists; Conditioning, Psychological; Disease Models, Animal; Dopamine; Electrophysiology; Male; Mice; Mice, Inbred Strains; Muscarinic Agonists; Neurons; Psychotic Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Schizophrenia; Thiadiazoles | 2000 |